Wellness & Lifestyle

Vizzhy offers an advanced heart health assessment for individuals with confirmed heart disease, moving beyond traditional scans and lab reports. It organizes genetic, inflammatory, metabolic, and molecular signals into a clear, time-based view to uncover the biological drivers behind cardiovascular risk. The platform reconstructs a patient's biology across multiple layers, computing disease drivers and providing physician-facing clinical intelligence. This includes precision drug assessment, care sequencing, nutrition and exercise guidance, and continuous monitoring, all integrated into existing cardiology workflows without EMR replacement.

HeartBeat.bio AG is a TechBio company dedicated to transforming cardiac drug discovery through its innovative platform. The core of their technology is the ability to generate human heart chamber models, called Cardioids, from induced pluripotent stem cells (iPSCs). These self-organizing Cardioids mimic human heart development and physiology, providing a precise and physiologically relevant model for cardiac diseases. The platform offers tailored models for conditions like myocardial fibrosis and cardiomyopathies, enabling advanced, disease-relevant drug testing. HeartBeat.bio integrates these predictive cardiac models with specialized assays in a fully automated, high-throughput 384-well format, supported by next-generation AI-driven data analytics, to accelerate and de-risk cardiac drug discovery.

Biorce offers Aika, an AI-native platform designed to accelerate clinical trials. Aika unifies solutions for protocol design, feasibility, and regulatory planning into one intuitive workspace, helping clinical teams reduce trial setup time, mitigate risks, and bring treatments to patients faster. The platform provides AI-accelerated protocol creation, aids in amendment prevention, and offers 100% explainable decisions based on approximately one million real trials. Biorce aims to address the challenge of explainability in AI for clinical trials, providing a transparency report for Aika. It is built by former CRO, clinicians, regulatory, and AI leaders, and is used across US, EU, and APAC by global clinical trial teams.

Emedgene, an Illumina Company, provides advanced software solutions for germline variant interpretation, specifically designed for rare disease genomics and other germline research applications. The platform integrates explainable AI and automation to streamline the analysis process, making it more efficient and accurate. It is part of Illumina's broader suite of software and informatics products, including BaseSpace Sequence Hub and DRAGEN Secondary Analysis. Emedgene aims to empower researchers and clinicians with data-driven insights, facilitating precision medicine programs and accelerating the pace of genomic discovery. The software is built to handle high-throughput diagnostics at scale, ensuring robust and reliable variant interpretation.

EarlyDiagnostics (EarlyDx) is dedicated to advancing cancer detection and precision medicine through its innovative liquid biopsy tests. The company has developed CancerRadar, a highly accurate and sensitive blood test for detecting and locating cancer. Additionally, EarlyDx offers EarlyDx-Cloud, a comprehensive bioinformatics solution designed to assist diagnostic companies in offering liquid biopsy tests for cancer detection, therapy selection, and treatment monitoring. Their core technologies include cfMethyl-seq for profiling cfDNA methylome, cfSNV for accurately calling mutations from blood, and cfTrack for non-invasive monitoring of cancer MRD, recurrence, and evolution. EarlyDx aims to provide accessible and reliable tools for early disease diagnostics.

Molecular Health is dedicated to building software solutions that leverage a unique symbiosis of human expertise, state-of-the-art data curation, and deep analytics to transform biomedical data into actionable insights. The company provides the MH Guide Case Annotation Solution (MH Guide CAS) for research laboratories to annotate genetic and molecular tumor alteration data with therapy associations, biomarkers, and clinical trials. For pharmaceutical and biotech professionals, Molecular Health offers advanced analyses using its Dataome Technology to create value in drug development. The platform focuses on providing comprehensive insights to guide research and optimize drug development processes.

Lucid Genomics is a leading platform designed to transform raw Long Read sequencing data into actionable insights for research, diagnostics, and drug discovery. This spin-off from Max Planck Institute leverages AI-driven algorithms to identify genetic variants and actionable insights with high precision. The platform covers variant detection, prioritization, interpretation, reporting, and trial matching. It integrates 3D genome architecture and multi-omics data, including RNA Seq and methylation, to unlock deep insights into non-coding regions and the Dark Genome. Lucid Genomics is trusted by experts for its ability to decrease false-positive structural variants by 81% and rank over 80% of known pathogenic variants in the top 10.

Angrow Co., Ltd. is a data-driven consumer-focused BioTech and MarTech company dedicated to developing effective products for the next 1 billion consumers. They integrate multidisciplinary applied science, including DNA Microarray Technology, Molecular and Synthetic Biology, and Pharmaceutical Sciences, with computer science-enabled incubation. Angrow utilizes an independent data fabric technology to accelerate the formulation of active ingredients into products. Their technological aesthetics combine bioinformatics, network pharmacology, and gene chip technology for modern science efficacy, ensuring pure, safe, and productive skincare. They also employ AI marketing tools like DMP, VOC, and SCRM to understand consumer responses and develop better products, alongside a Future-Proof Enterprise Business Capacity (EBC) System for operational efficiency.

Angstrom AI revolutionizes preclinical drug development by leveraging advanced AI physics simulations to replace time-consuming and costly lab experiments. The platform provides highly accurate computations for critical molecular properties such as solubility, lipophilicity, and crystal structure stability, matching experimental error. It excels in calculating free energy differences, binding conformations, and hydration sites with ab initio accuracy, significantly accelerating the drug discovery pipeline. Angstrom AI's technology is built upon cutting-edge research, including methods for computing solvation free energies with experimental accuracy and equivariant generative models for molecular conformations, enabling faster sampling than traditional molecular dynamics.

Mithrl is a scientific decision engine designed for enterprise R&D in the biomedical field. It significantly accelerates R&D cycles, reducing the time between experiments from weeks to an average of 32 times faster. The platform provides auditable, biologically grounded insights essential for high-stakes decisions. Mithrl helps researchers analyze omics data, contextualize findings with scientific rigor, and derive actionable insights. Key capabilities include identifying novel drug targets, discovering new biomarkers, interpreting results within a biological context, and decoding mechanisms of action, all by combining experimental data with Mithrl’s knowledge graphs.

NTT RESEARCH is dedicated to fundamental research across various scientific domains, including physics, cryptography, and medical informatics. The organization's core mission is to upgrade reality by conducting basic research and developing advanced technologies that seamlessly integrate into daily life, fostering positive change for humanity. Key research areas include the Physics Informatics Lab, Cryptography and Information Security (CIS) Lab, and Medical and Health Informatics (MEI) Lab, with a focus on initiatives like the Bio Digital Twin. NTT RESEARCH aims to drive innovation that improves health outcomes through precision medicine and advances in secure data solutions.

Copeia develops digital health solutions to support individualized medical cannabis therapy, catering to both patients and healthcare professionals including doctors, pharmacies, pharmaceutical companies, and insurers. The platform offers data-based solutions such as a cannabis product database for transparent therapy, tools for initial assessment, documentation, and cost reimbursement applications, and individualized dosage and titration plans. Copeia also provides a Physician Experience Platform (PEP) for medical professionals to share knowledge and improve therapy through structured case studies. Its innovative solutions simplify time-consuming processes, support patient-focused therapy, and offer transparent overviews of available cannabis medicines, including access to lab analyses.

Pre-Clinical Trial Solution is an intelligent, multi-platform technology solution designed to simplify and streamline pre-clinical trial processes. It offers an AI-driven Feasibility Questionnaire Assistant (FQA) to expedite and enhance accuracy in feasibility assessments. Users can manage pre-clinical trial tasks, complete feasibility questionnaires with AI-driven suggestions, and track progress from a single, secure location. The platform ensures data security through two-factor authentication and robust privacy measures, providing effortless auto-fill questionnaires, streamlined workflow management, and enhanced data accuracy.

CytoHub Inc. is at the forefront of cardiac science, utilizing an AI-driven platform to accelerate safer drug development and support diverse cardiac therapeutic programs. Their core offering includes CardioVive™, standardized iPSC-derived human mini-hearts that recapitulate native cardiac cell-type diversity, suitable for safety, efficacy, and disease modeling. Complementing this is BioEngineAI™, an AI-driven multimodal analytics engine that ingests, quality-controls, and interprets complex biological datasets, enabling consistent feature extraction and traceable outputs. This integrated platform aims to transform cardiac drug development by providing reproducible, human-relevant insights, addressing the limitations of traditional animal models and simplified cell systems.

Tailor Bio is at the forefront of developing targeted therapies for cancers characterized by chromosomal instability. Leveraging an advanced AI-driven drug discovery platform, the company aims to accelerate the identification and development of precision medicines. This innovative approach addresses a significant genomic phenomenon present in a large percentage of cancers, offering the potential for more effective and personalized treatment options. By focusing on specific genetic markers, Tailor Bio seeks to improve patient outcomes and revolutionize cancer treatment.

Siftlink SA is a sophisticated Data & Analytics tool designed to bridge the gap between scientific data and business insights, specifically within the biology and chemistry sectors. It integrates advanced analytics and AI capabilities to provide strategic business intelligence. The platform assists clients in developing market-leading products by offering precise insights and impactful data analysis. By combining scientific rigor with commercial understanding, Siftlink aims to deliver a comprehensive solution for product development in the life sciences, enabling informed decision-making and fostering innovation.

PharmEnable Therapeutics is at the forefront of small molecule drug discovery, leveraging advanced AI to access previously inaccessible chemical spaces. Their platform is designed to push the boundaries of what's possible with small molecule therapeutics, enabling the discovery of novel compounds for challenging and data-sparse targets. By overcoming chemical space bottlenecks, PharmEnable aims to develop life-changing medicines, particularly focusing on targets that are inaccessible with traditional drug discovery methods. The company is a spin-out from the University of Cambridge, UK, and is actively building a rapidly growing pipeline of innovative first- and best-in-class drugs, offering therapeutic differentiation.

DeepForrest AI offers specialized AI solutions designed to enhance compliance and operational efficiency within the life sciences and regulatory affairs sectors. Its flagship product, Harmony, streamlines regulatory authoring and lifecycle management, ensuring audit-ready submissions and faster processing. The platform also features RootSense for accelerated investigations and PV-Lit Assistant for smarter pharmacovigilance literature automation. DeepForrest AI is built specifically for regulated life sciences workflows, adhering to standards like 21 CFR Part 11, and incorporates human-in-the-loop AI to combine automation with expert oversight, ensuring accuracy and accountability. This approach helps organizations achieve faster submissions, higher accuracy, and significantly reduced manual effort.

OpenProtein.AI offers a sophisticated cloud platform for AI-driven protein design and optimization, leveraging advanced models like PoET-2, AlphaFold2, ESM2, and Clustal Omega. The platform helps users reduce costs, accelerate projects, and achieve better results in fewer rounds by eliminating guesswork and streamlining workflows. It allows for the design of optimized variant libraries, comparison of library outcomes, and visualization of predicted protein structures. OpenProtein.AI supports projects of all sizes, from 96-well plates to high-throughput pipelines, and can optimize any protein for various properties like activity, expressibility, and thermo stability. The technology learns from natural protein sequence databases and user-specific data to generate novel, functional proteins.

GraphTx is a precision immunology techbio company focused on decoding immune dysfunction at scale. The platform captures the dynamic behavior of live patient immune cells, preserving the complexity that determines therapeutic response. This approach, termed 'Immune Mapping LITL Perturbation,' aims to decode patient variation and front-load clinical success in drug discovery. GraphTx utilizes functional profiling to identify disease-specific immunomodulatory responses and novel therapeutic targets, as evidenced by their research in rheumatoid arthritis and systemic inflammation. The company partners with other organizations, such as Parse Biosciences and BIIE, to advance precision immunology.

Cyntegrity offers an AI-augmented Risk-Based Quality Management (RBQM) solution designed for scalable, hybrid, and decentralized clinical trials. The platform supports ICH E6(R3) and E8(R1) expectations by strengthening human judgment with traceable decisions, helping teams understand not only what changed but why. Key features include a MyRBQM® Portal for central monitoring, predictive risk signals, data quality oversight, and medical monitoring. It helps eliminate global oversight gaps, detect risks earlier, and build sponsor confidence through transparent, audit-ready reporting. Cyntegrity also provides the MyRBQM® Academy for change management and skill development in RBQM.

MaSIF (Molecular Surface Interaction Fingerprints) is an open-source proof-of-concept method leveraging geometric deep learning to analyze patterns in protein surfaces crucial for biomolecular interactions. It decomposes surfaces into radial patches, assigning geometric and chemical features to each point, then computes descriptors for these patches. The tool includes a protocol for preparing protein structure files, converting them into feature-rich surfaces, and decomposing them into patches. MaSIF offers three key applications: MaSIF-ligand for predicting ligand binding pockets, MaSIF-site for predicting protein-protein interaction sites, and MaSIF-search for ultrafast scanning of surfaces to predict protein-protein complex configurations. It is designed for researchers in protein-surface learning tasks.

Kantify offers Sapian, an AI-driven small molecule discovery engine designed to overcome challenges in drug discovery, particularly for "undruggable" targets. Sapian utilizes novel AI models trained on hundreds of millions of data points to identify IP-clean chemistry from a library of over 10 billion possible candidates. It excels even for targets lacking 3D structures or known modulators, demonstrating validated success across various target categories like ion channels and antigens. The platform significantly accelerates the discovery process, screening 10 billion compounds in less than a day, a 10,000-fold increase over traditional methods. Sapian also predicts pharmacodynamic and pharmacokinetic profiles across the eukaryotic proteome, enabling the selection of selective drugs in silico and bringing predictability and risk mitigation to drug discovery.

Prescience Insilico is a leading organization specializing in AI-driven drug discovery and high-performance computing for material and life sciences. Their flagship product, PRinS3, is an AI-driven software platform tailored for drug discovery experts. It seamlessly incorporates the design of new chemical entities, scalable high-throughput screening using state-of-the-art physics-based methods, and robust support for cloud and high-performance computing (HPC) infrastructure. Beyond software, Prescience Insilico offers R&D services for materials and life science, utilizing multiscale computational chemistry to accelerate innovation and meet sustainability targets. They also provide digital transformation services, building custom digital stacks with physics-informed ML models to enhance collaboration and data management for research outcomes.